• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

手机动态码快速登录

手机号快速注册登录

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
194622 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
1 A; `( Q, ^  I- e( M" m' ?1 X& D0 f' l; i7 N

- X8 b$ J6 I* tSub-category:
7 _, ~- [1 q( q( _  O$ zMolecular Targets ( _& d) w3 e/ E3 L( V

2 b& k/ [  u1 a1 ~3 [6 ~% F# U$ n- ^; Q& h1 ]
Category:2 z0 B& G7 J9 H. e0 H
Tumor Biology
2 j/ U( s+ A) a( X8 O$ B" }3 X8 E( ?8 r, u
/ N; j, @; L6 \1 x$ N
Meeting:
, m, K) A) g8 x  ?% |2011 ASCO Annual Meeting 5 @- i3 [$ {6 n, {4 r, o; r- H

0 X8 X0 h: }! B1 E0 ?
6 o5 ]6 A4 m0 |( S" L6 K: _$ }6 jSession Type and Session Title:) b9 \9 t0 K; k! |2 U) y
Poster Discussion Session, Tumor Biology 5 l* ~' L- p/ M. ^$ x& o( u1 H4 |
% N: v1 m& q: {! [2 y/ @

% G- L3 C" V4 N3 fAbstract No:, @' }9 c" ~, B: {6 d* c% x3 d) V
10517 7 w" o/ u# \! k# c' w- X

  s5 }3 N5 q$ ]7 A7 N; ^5 N
5 Q* B; b3 @7 L5 T' s8 u: @/ iCitation:5 P% z# g- C" d8 F+ j1 t
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) M- X! r' g4 [. S$ }. K# U
4 T. p% F4 x0 J- P4 y% o0 S. j" m1 F6 M3 {, Y
Author(s):
+ F0 S! a, F4 b7 [9 U( [2 @- D7 lJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 D, @" E3 G. M( m* Z6 q, v5 P4 w- e& E1 ^( Z+ g+ {

/ T1 [; T0 G& I0 ]4 o( h" M6 ?! `
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- B) l6 T# W$ R! S

& n& P5 w- L; W8 yAbstract Disclosures+ u! m) u4 A7 `" h' [

3 K2 A- ^6 t7 E6 P2 J' q( wAbstract:/ g6 s$ \+ d$ f

. W0 Z+ ]- |4 n2 T# J1 k; \/ k4 [1 g: m/ T7 a& E3 H! m
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." _( Q* x! q" I$ \( q  T1 N4 b
% h  w+ O3 }: ~3 A: t+ e* i

) L% W* R7 P/ n8 j9 w
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 & o# l# f8 G! l- {
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

! A+ R# ~, w8 O2 b. p" U6 I化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ( F- ^2 M5 r, q
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。1 b( n/ R7 l( `8 R0 r: I
ALK一个指标医院要900多 ...
7 d2 E' V" G6 Y$ q+ E
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 n7 Q" I) d- H! H1 ]0 }

2 s2 Z% R; o% c! N  \  s1 l% V+ M现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册 手机动态码快速登录

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表